← Leaderboards
Matthew Raymond Smith
Massachusetts General Hospital
$3,230,660
Attributed
$3,230,660
Total exposure
9
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $198.4K · FY2005–16$200K$150K$100K$50K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
Funding mix
By agency
NIH$3,230,660 · 9
By mechanism
K24$1,894,231 · 1
M01$720,549 · 7
R21$615,880 · 1
Top collaborators
No co-investigators on record.
Most similar at Massachusetts General Hospital
Same institution · by research overlap
- Steven Kyle Grinspoon$75,757,679
- William F Crowley$27,565,527
- Thomas J Gardella$10,202,128
- Karen K Miller$23,499,917
- Harald W. Jueppner$19,159,604
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchPatient Oriented ResearchHuman SubjectResearch PersonnelMaleProstate NeoplasmsMalignant Neoplasm Of ProstateHuman Therapy EvaluationAndrogensFundingAwardDrug Adverse EffectMalignant NeoplasmsPreventionMetastatic Neoplasm To The BoneProgramsCancer CenterMassachusettsCancer SurvivorshipPeer ReviewMentorsPreventOsteoporosisBone Density
Grant awards (27)
Midcareer Investigator Award$185,972
K24 · FY2016 · CA · contact PI
Midcareer Investigator Award$185,972
K24 · FY2015 · CA · contact PI
Midcareer Investigator Award$185,972
K24 · FY2014 · CA · contact PI
Midcareer Investigator Award$185,972
K24 · FY2013 · CA · contact PI
Midcareer Investigator Award$185,972
K24 · FY2012 · CA · contact PI
Midcareer Investigator Award$195,504
K24 · FY2011 · CA · contact PI
Midcareer Investigator Award$195,504
K24 · FY2010 · CA · contact PI
Midcareer Investigator Award$193,249
K24 · FY2009 · CA · contact PI
Midcareer Investigator Award$191,090
K24 · FY2008 · CA · contact PI
INSULIN RESISTANCE$6,314
M01 · FY2008 · RR · contact PI
LIFESTYLE INTERVENTION OF GNRH THERAPY FOR PROSTATE CA$971
M01 · FY2008 · RR · contact PI
Midcareer Investigator Award$189,024
K24 · FY2007 · CA · contact PI
CARDIOVASCULAR DIS RISK DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CA$22,588
M01 · FY2006 · RR · contact PI
CARDIOVASCULAR DIS RISK DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CA$9,084
M01 · FY2005 · RR
RALOXIFENE/BONE LOSS IN MEN WITH PROSTATE CANCER$1,912
M01 · FY2005 · RR
BICALUTAMIDE VERSUS LEUPROLIDE ACETATE: HORMONAL THERAPY FOR PROSTATE CANCER$478
M01 · FY2005 · RR
ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy$307,940
R21 · FY2004 · CA
CARDIOVASCULAR DIS. RISK DURING ANDROGEN DEPRIVATION THERAPY FOR PROSTATE CA$34,843
M01 · FY2004 · RR
RALOXIFENE/BONE LOSS IN MEN WITH PROSTATE CANCER$27,100
M01 · FY2004 · RR
BICALUTAMIDE VERSUS LEUPROLIDE ACETATE: HORMONAL THERAPY FOR PROSTATE CANCER$14,380
M01 · FY2004 · RR
ADAM: Androgen Deprivation vs. Antiandrogen Monotherapy$307,940
R21 · FY2003 · CA
PREVENTION OF OSTEOPOROSIS IN MEN W/ ANDROGEN DEPRIVATION &PROSTATE CANCER$200,768
M01 · FY2002 · RR
PREVENTION OF OSTEOPOROSIS IN MEN W/ ANDROGEN DEPRIVATION &PROSTATE CANCER$200,768
M01 · FY2002 · RR
PREVENTION OF OSTEOPOROSIS IN MEN W/ ANDROGEN DEPRIVATION &PROSTATE CANCER$200,768
M01 · FY2001 · RR
PREVENTION OF OSTEOPOROSIS IN MEN W/ ANDROGEN DEPRIVATION &PROSTATE CANCER$0
M01 · FY2001 · RR
PREVENTION OF OSTEOPOROSIS IN MEN W/ ANDROGEN DEPRIVATION &PROSTATE CANCER$575
M01 · FY2000 · RR
PREVENTION OF OSTEOPOROSIS IN MEN W/ ANDROGEN DEPRIVATION &PROSTATE CANCER$0
M01 · FY2000 · RR